Last checked at 
(Sharecast News) - Medical imaging technology company Polarean Imaging has received an additional research unit order for a '9820 Xenon Polariser' system from the University of British Columbia (UBC), it announced on Monday.
The AIM-traded firm said it would be the second system installation at UBC, following the original order in November 2019 which was initially installed at BC Children's Hospital, while construction was carried out on its intended original site at St. Paul's.
As with the original system, the company said the new unit would continue to support UBC's pulmonary disease research programme using hyperpolarised gas imaging.
BC Children's is a major paediatric research and teaching hospital, and is the "most well-known facility" in the province for dealing in juvenile health, the board said.
"We value our long-standing relationship with UBC, a globally recognised research group, and we are excited that they are adding an additional polariser system to expand their research into the clinical applications of this emerging and much needed technology," said chief executive officer Richard Hullihen.
"We are also pleased to be able to continue to expand our paediatric research cluster, which also includes Cincinnati Children's Hospital Medical Center and Toronto SickKids Hospital."
At 1155 BST, shares in Polarean Imaging were up 5.88% at 97.41p.
29 Aug 2023 11:36
IN BRIEF: Polarean Imaging product cleared for US Medicare payments
Polarean Imaging PLC - London-based medical imaging technology developer - Says the US Centers for Medicare & Medicaid Services has established a new reimbursement code for Polarean's Xenoview or 'xenon XE 129' magnetic resonance imaging technology. Code "enables healthcare providers a path to bill for 'magnetic resonance imaging with [the] inhaled hyperpolarised xenon-129 contrast agent...including preparation and administration of agent'." Polarean expects to be informed of the new code's payment level "in the coming weeks".
Read more